Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1989 1
1990 2
1992 1
1993 1
1996 2
1997 3
1998 3
1999 2
2001 1
2002 3
2003 4
2004 7
2005 6
2006 1
2007 4
2008 6
2009 12
2010 8
2011 14
2012 17
2013 21
2014 38
2015 33
2016 41
2017 28
2018 33
2019 51
2020 50
2021 62
2022 67
2023 59
2024 55
2025 58
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

622 results

Results by year

Filters applied: . Clear all
Page 1
Designed endocytosis-inducing proteins degrade targets and amplify signals.
Huang B, Abedi M, Ahn G, Coventry B, Sappington I, Tang C, Wang R, Schlichthaerle T, Zhang JZ, Wang Y, Goreshnik I, Chiu CW, Chazin-Gray A, Chan S, Gerben S, Murray A, Wang S, O'Neill J, Yi L, Yeh R, Misquith A, Wolf A, Tomasovic LM, Piraner DI, Duran Gonzalez MJ, Bennett NR, Venkatesh P, Ahlrichs M, Dobbins C, Yang W, Wang X, Sahtoe DD, Vafeados D, Mout R, Shivaei S, Cao L, Carter L, Stewart L, Spangler JB, Roybal KT, Greisen PJ, Li X, Bernardes GJL, Bertozzi CR, Baker D. Huang B, et al. Nature. 2025 Feb;638(8051):796-804. doi: 10.1038/s41586-024-07948-2. Epub 2024 Sep 25. Nature. 2025. PMID: 39322662 Free PMC article.
The Reply.
Abedi V, Zand R. Abedi V, et al. Am J Med. 2019 Oct;132(10):e751. doi: 10.1016/j.amjmed.2019.06.037. Am J Med. 2019. PMID: 31685188 No abstract available.
The Reply.
Abedi V, Zand R. Abedi V, et al. Am J Med. 2020 Feb;133(2):e69. doi: 10.1016/j.amjmed.2019.10.012. Am J Med. 2020. PMID: 31954482 No abstract available.
The Reply.
Abedi V, Zand R. Abedi V, et al. Am J Med. 2020 Feb;133(2):e67. doi: 10.1016/j.amjmed.2019.08.015. Am J Med. 2020. PMID: 31954480 No abstract available.
Biomolecular Ultrasound and Sonogenetics.
Maresca D, Lakshmanan A, Abedi M, Bar-Zion A, Farhadi A, Lu GJ, Szablowski JO, Wu D, Yoo S, Shapiro MG. Maresca D, et al. Annu Rev Chem Biomol Eng. 2018 Jun 7;9:229-252. doi: 10.1146/annurev-chembioeng-060817-084034. Epub 2018 Mar 26. Annu Rev Chem Biomol Eng. 2018. PMID: 29579400 Free PMC article. Review.
Thermal Control of Engineered T-cells.
Abedi MH, Lee J, Piraner DI, Shapiro MG. Abedi MH, et al. ACS Synth Biol. 2020 Aug 21;9(8):1941-1950. doi: 10.1021/acssynbio.0c00238. Epub 2020 Aug 4. ACS Synth Biol. 2020. PMID: 32786924
Designed Endocytosis-Triggering Proteins mediate Targeted Degradation.
Huang B, Abedi M, Ahn G, Coventry B, Sappington I, Wang R, Schlichthaerle T, Zhang JZ, Wang Y, Goreshnik I, Chiu CW, Chazin-Gray A, Chan S, Gerben S, Murray A, Wang S, O'Neill J, Yeh R, Misquith A, Wolf A, Tomasovic LM, Piraner DI, Gonzalez MJD, Bennett NR, Venkatesh P, Satoe D, Ahlrichs M, Dobbins C, Yang W, Wang X, Vafeados D, Mout R, Shivaei S, Cao L, Carter L, Stewart L, Spangler JB, Bernardes GJL, Roybal KT, Greisen P Jr, Li X, Bertozzi C, Baker D. Huang B, et al. bioRxiv [Preprint]. 2023 Sep 20:2023.08.19.553321. doi: 10.1101/2023.08.19.553321. bioRxiv. 2023. PMID: 37781607 Free PMC article. Preprint.
Impact of SGLT2 inhibitors on myocardial fibrosis in diabetic HFpEF: a longitudinal study.
Albulushi A, Askari KM, Al-Abedi AM, Al-Kulaibi MA, Hasan MS, Hosseini Z, Al-Rahman MT, Tanoh DB, Hasan AS, Al-Helli Y, Basouni A. Albulushi A, et al. Eur J Med Res. 2025 Jul 8;30(1):592. doi: 10.1186/s40001-025-02834-7. Eur J Med Res. 2025. PMID: 40624547 Free PMC article. Clinical Trial.

RESULTS: Dapagliflozin significantly reduced myocardial fibrosis (mean deltaECV: - 3.5% [95% CI - 4.2 to - 2.8]) compared to placebo (- 0.8% [95% CI - 1.3 to - 0.4]; p < 0.001). Additional benefits included greater reductions in LVMI (- 8.2 g/m(2) vs. - 2.1 g/m(2); p

…
RESULTS: Dapagliflozin significantly reduced myocardial fibrosis (mean deltaECV: - 3.5% [95% CI - 4.2 to - 2.8]) compared to placebo (- 0.8% …
622 results